Ground is officially broken on CPI's £38m National Biologics Manufacturing Centre

Ground is officially broken on CPI's £38m National Biologics Manufacturing Centre

The Centre for Process Innovation (CPI) officially breaks ground on its state of the art National Biologics Manufacturing Centre (NBMC) at its new Central Park, Darlington site. Steve Bagshaw, CEO Fujifilm Diosynth Biotechnologies, and Sandy Anderson, OBE, Chair of Tees Valley Unlimited, are in attendance on a day which also provides an opportunity for a unique insight into the current biologics industry and the potential of its latest facility.

Due for completion in 2015, the centre is part of the Government's 'Strategy for UK Life Sciences' launched in 2011 to strengthen the UK's life-science sector. CPI was selected to establish and manage the new £38 million centre which will encourage innovative solutions in the UK healthcare market.

The purpose of the NBMC is to enable the biopharmaceutical industry to capitalise on its strong research and development pipeline and make more therapies available for unmet clinical needs. CPI supports the commercialisation of research by promoting collaboration with industry across the supply chain from research through to manufacture and clinic.

CPI's team of scientists, engineers and sector specialists will help companies of all sizes to develop, demonstrate, prototype and scale-up innovations that could be beneficial to biologics manufacture and provision, from initial programme scoping and planning through to process demonstration and scale-up.

Steve Bagshaw, CEO Fujifilm Diosynth Biotechnologies says: "The NBMC is an excellent opportunity to bring industry, academia and the funding agencies together to create the best possible environment for UK Biotechnology to grow."

Sandy Anderson, OBE, Chair of Tees Valley Unlimited says: "This project is an excellent example of what can be achieved through genuine partnership. The healthcare industry and CPI have worked closely with Darlington Council and TVU, the Local Enterprise Partnership for the Tees Valley, to make this investment in innovate technology possible."

CPI's Director of Biologics, Dr Chris Dowle, says: "We are delighted to herald this groundbreaking to progress the journey to the new centre as we work with industry and academia to deliver new innovation to enhance the competiveness of the UK biologics economy."

Bill Dixon, Leader of Darlington Borough Council and Deputy Chairman of Tees Valley Unlimited says: "This is a fantastic indication of how far Central Park has come – it sends out a clear message that people want to invest in Darlington.

"We beat off tough competition to secure this national centre for excellence and it will provide the foundations for a biomedical and pharmaceutical industry to prosper in Darlington. The kinds of jobs it will create are highly skilled and knowledge-based which is great news for young people who want to stay in the area and secure a skilled job."

Contacts

Helen Briggs

Marketing Executive

The Centre for Process Innovation (CPI)

T: +44 (0)1642 455 340

M: +44 (0)7920818828

  @ukCPI  | LinkedIn | www.uk-cpi.com   [email protected]

Notes

About CPI

The Centre for Process Innovation is a UK-based technology innovation centre and part of the High Value Manufacturing Catapult. We use applied knowledge in science and engineering combined with state of the art development facilities to enable our clients to develop, prove, prototype and scale up the next generation of products and processes. Our open innovation model enables clients to develop products and prove processes with minimal risk. We provide assets and expertise so our customers can demonstrate the process before investing substantial amounts of money in capital equipment and training. New products and processes can be shown to be feasible; on paper, in the lab and in the plant before being manufactured at an industrial scale. By utilising our proven assets and expertise companies can take their products and processes to market faster. There is no down time in production as all of the process development is completed offsite and our technology transfer and engineering teams can help companies to transfer the product or process into full scale production at speed.

About Biologics

Biologics are defined as medicinal products that are created by biological processes rather than via chemical synthesis. Biologics are generated from living systems, usually cultured mammalian or microbial cells which have been selected based on their ability to produce the molecule of interest in economic quantities. The use of biologics as therapeutics has steadily increased over the past decade; currently some of the biggest selling drugs are biologics which are used to treat various forms of cancer, autoimmune diseases such as arthritis, and other diseases which are caused by a shortage of signalling proteins such as hormones and growth factors.

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.